Analysis of Growth Drivers in the Biliary Tract Cancer Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Source: Newsfilter
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPX
Wall Street analysts forecast CMPX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.930
Low
8.00
Averages
12.67
High
24.00
Current: 1.930
Low
8.00
Averages
12.67
High
24.00
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compass Therapeutics Under Investigation as Stock Plummets 64.41%
- Investigation Launched: Pomerantz LLP is investigating on behalf of Compass Therapeutics investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns about corporate governance and compliance.
- Clinical Trial Results: On April 27, 2026, Compass announced that its phase 2/3 study met the key secondary endpoint of progression-free survival, yet failed to meet the overall survival endpoint, indicating limitations in the drug's efficacy.
- Stock Price Plunge: Following the disappointing clinical trial results, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, severely impacting investor confidence.
- Legal Implications: The stock price drop and subsequent investigation may expose the company to class action lawsuits, further exacerbating uncertainty in the market and increasing risks for investors.
See More
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating whether Compass Therapeutics, Inc. has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and seek legal remedies.
- Clinical Trial Results: On April 27, 2026, Compass announced that its drug tovecimig met a key secondary endpoint in treating biliary tract cancer, yet failed to meet another critical secondary endpoint related to overall survival, indicating the complexity of the study results.
- Stock Price Plunge: Following the disappointing clinical trial results, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Context: Pomerantz LLP is a renowned securities class action law firm with over 85 years of experience, focusing on advocating for victims of securities fraud and corporate misconduct, having historically recovered multimillion-dollar damages for class members.
See More
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors in Compass Therapeutics, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- Clinical Trial Results: On April 27, 2026, Compass announced results from a phase 2/3 study indicating that while its drug tovecimig met the key secondary endpoint of progression-free survival, it failed to meet the overall survival endpoint, undermining market confidence.
- Stock Price Plunge: Following this news, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, reflecting a pessimistic sentiment among investors regarding the company's future prospects.
- Potential Legal Consequences: As a prominent firm in securities class action litigation, Pomerantz LLP may provide legal support to affected investors, potentially exacerbating the legal and financial risks faced by the company.
See More
Compass Therapeutics Announces May Investor Events Participation
- Investor Event Schedule: Compass Therapeutics will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 1:30 PM ET, which is expected to attract significant investor interest in its oncology therapies.
- Online Forum Participation: The company will also take part in the Stifel Virtual Targeted Oncology Forum on May 20, 2026, at 11:30 AM ET, providing an opportunity for interaction with potential investors and enhancing its market visibility.
- One-on-One Meeting Opportunities: Management will be available for one-on-one meetings during all events, allowing investors to deepen their understanding of the company's research pipeline by contacting their respective representatives to request meetings.
- Company Background Overview: Founded in 2014, Compass Therapeutics focuses on developing antibody-based therapeutics aimed at addressing multiple diseases by modulating angiogenesis and activating immune responses within the tumor microenvironment, showcasing strong market potential.
See More
Compass Therapeutics Reports Q1 Results with Cash Runway Until 2028
- Financial Performance: Compass Therapeutics reported a Q1 2026 GAAP EPS of -$0.10, aligning with market expectations, indicating stability in financial management despite ongoing losses.
- Cash Position: As of March 31, 2026, the company held $195 million in cash and marketable securities, down from $209 million on December 31, 2025, representing a $14 million decrease; however, the anticipated cash runway extends into 2028, ensuring operational stability.
- Cash Usage in Operations: During the first quarter, Compass utilized $18 million in net cash for operating activities, partially offset by $4 million from common stock exercises, reflecting ongoing investments in R&D and operations.
- Market Reaction: Despite positive secondary endpoint results from the COMPANION-002 study, the stock price of Compass Therapeutics fell due to missing the overall survival endpoint, indicating market caution regarding its long-term potential.
See More
Tovecimig Shows Significant Survival Benefit in Biliary Tract Cancer Trial
- Clinical Trial Results: In a Phase 2/3 study of biliary tract cancer patients, the combination of tovecimig and paclitaxel demonstrated a progression-free survival (PFS) of 4.7 months, significantly better than the 2.6 months for paclitaxel alone (HR=0.44, p<0.0001), indicating tovecimig's potential as a new second-line treatment option.
- FDA Meeting Planned: Tovecimig received Orphan Drug Designation in April 2026, and the company plans to meet with the FDA prior to its Biologics License Application (BLA) submission, paving the way for market access to address the urgent needs of biliary tract cancer patients.
- Financial Position: As of Q1 2026, the company reported $195 million in cash and marketable securities, expected to fund operations into 2028, although this reflects a decrease from $209 million at the end of 2025, highlighting ongoing investments in R&D.
- R&D Progress: Clinical trials for CTX-8371 and CTX-10726 are underway, with the former showing deep responses in three cancer types and initial data from the latter expected in Q4 2026, further enhancing the company's competitive edge in oncology therapeutics.
See More
Compass Therapeutics Under Investigation as Stock Plummets 64.41%
- Investigation Launched: Pomerantz LLP is investigating on behalf of Compass Therapeutics investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns about corporate governance and compliance.
- Clinical Trial Results: On April 27, 2026, Compass announced that its phase 2/3 study met the key secondary endpoint of progression-free survival, yet failed to meet the overall survival endpoint, indicating limitations in the drug's efficacy.
- Stock Price Plunge: Following the disappointing clinical trial results, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, severely impacting investor confidence.
- Legal Implications: The stock price drop and subsequent investigation may expose the company to class action lawsuits, further exacerbating uncertainty in the market and increasing risks for investors.
See More
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating whether Compass Therapeutics, Inc. has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and seek legal remedies.
- Clinical Trial Results: On April 27, 2026, Compass announced that its drug tovecimig met a key secondary endpoint in treating biliary tract cancer, yet failed to meet another critical secondary endpoint related to overall survival, indicating the complexity of the study results.
- Stock Price Plunge: Following the disappointing clinical trial results, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Context: Pomerantz LLP is a renowned securities class action law firm with over 85 years of experience, focusing on advocating for victims of securities fraud and corporate misconduct, having historically recovered multimillion-dollar damages for class members.
See More
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors in Compass Therapeutics, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- Clinical Trial Results: On April 27, 2026, Compass announced results from a phase 2/3 study indicating that while its drug tovecimig met the key secondary endpoint of progression-free survival, it failed to meet the overall survival endpoint, undermining market confidence.
- Stock Price Plunge: Following this news, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, reflecting a pessimistic sentiment among investors regarding the company's future prospects.
- Potential Legal Consequences: As a prominent firm in securities class action litigation, Pomerantz LLP may provide legal support to affected investors, potentially exacerbating the legal and financial risks faced by the company.
See More
Compass Therapeutics Announces May Investor Events Participation
- Investor Event Schedule: Compass Therapeutics will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 1:30 PM ET, which is expected to attract significant investor interest in its oncology therapies.
- Online Forum Participation: The company will also take part in the Stifel Virtual Targeted Oncology Forum on May 20, 2026, at 11:30 AM ET, providing an opportunity for interaction with potential investors and enhancing its market visibility.
- One-on-One Meeting Opportunities: Management will be available for one-on-one meetings during all events, allowing investors to deepen their understanding of the company's research pipeline by contacting their respective representatives to request meetings.
- Company Background Overview: Founded in 2014, Compass Therapeutics focuses on developing antibody-based therapeutics aimed at addressing multiple diseases by modulating angiogenesis and activating immune responses within the tumor microenvironment, showcasing strong market potential.
See More
Compass Therapeutics Reports Q1 Results with Cash Runway Until 2028
- Financial Performance: Compass Therapeutics reported a Q1 2026 GAAP EPS of -$0.10, aligning with market expectations, indicating stability in financial management despite ongoing losses.
- Cash Position: As of March 31, 2026, the company held $195 million in cash and marketable securities, down from $209 million on December 31, 2025, representing a $14 million decrease; however, the anticipated cash runway extends into 2028, ensuring operational stability.
- Cash Usage in Operations: During the first quarter, Compass utilized $18 million in net cash for operating activities, partially offset by $4 million from common stock exercises, reflecting ongoing investments in R&D and operations.
- Market Reaction: Despite positive secondary endpoint results from the COMPANION-002 study, the stock price of Compass Therapeutics fell due to missing the overall survival endpoint, indicating market caution regarding its long-term potential.
See More
Tovecimig Shows Significant Survival Benefit in Biliary Tract Cancer Trial
- Clinical Trial Results: In a Phase 2/3 study of biliary tract cancer patients, the combination of tovecimig and paclitaxel demonstrated a progression-free survival (PFS) of 4.7 months, significantly better than the 2.6 months for paclitaxel alone (HR=0.44, p<0.0001), indicating tovecimig's potential as a new second-line treatment option.
- FDA Meeting Planned: Tovecimig received Orphan Drug Designation in April 2026, and the company plans to meet with the FDA prior to its Biologics License Application (BLA) submission, paving the way for market access to address the urgent needs of biliary tract cancer patients.
- Financial Position: As of Q1 2026, the company reported $195 million in cash and marketable securities, expected to fund operations into 2028, although this reflects a decrease from $209 million at the end of 2025, highlighting ongoing investments in R&D.
- R&D Progress: Clinical trials for CTX-8371 and CTX-10726 are underway, with the former showing deep responses in three cancer types and initial data from the latter expected in Q4 2026, further enhancing the company's competitive edge in oncology therapeutics.
See More
